This listing of claims will replace all prior versions, and listings, of the claims in the application:

## **Listing of Claims:**

Claim 1. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin.

Claim 2. (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a complex or solution of the therapeutically effective amount of Betalapachone, or a derivative or analog thereof, and the pharmaceutically acceptable solubilizing carrier molecule.

Claims 3-5. (Cancelled)

Claim 6. (Previously Presented) The pharmaceutical composition of claim 1, wherein the beta-cyclodextrin is hydroxypropyl-beta-cyclodextrin.

Claims 7-8. (Cancelled)

Claim 9. (Previously Presented) The pharmaceutical composition of claim 1, wherein the concentration of Beta-lapachone in solution is at least 1 mg/ml.

Claim 10. (Cancelled)

Claim 11. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin, which when diluted with an aqueous solution for parenteral administration, remains soluble in the aqueous solution.

Claim 12. (Previously Presented) The pharmaceutical composition of claim 11, wherein the therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, is complexed with the pharmaceutically acceptable solubilizing carrier molecule.

Claims 13-14. (Cancelled).

Claim 15. (Previously Presented) The pharmaceutical composition of claim 11, wherein the beta-cyclodextrin is hydroxypropyl-beta-cyclodextrin.

Claim 16-17. (Cancelled).

Claim 18. (Original) The pharmaceutical composition of claim 11, wherein the concentration of Beta-lapachone in solution is at least 1 mg/ml.

Claim 19. (Original) The pharmaceutical composition of claim 12, wherein the complex comprises a dosage unit in the range between 0.1 mg/kg to 10 mg/kg administered from between twice weekly to once every four weeks.

Claim 20. (Cancelled).

Claim 21. (Previously Presented) A formulation comprising a therapeutically effective amount of comprising Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin, wherein the formulation can be freeze-dried and when subsequently reconstituted in aqueous solution is soluble.

Claim 22. (Original) The formulation of claim 21, wherein the Beta-lapachone, or a derivative or analog thereof is complexed with the pharmaceutically acceptable solubilizing carrier molecule.

Claims 23-24. (Cancelled).

Claim 25. (Previously Presented) The formulation of claim 21, wherein the beta-cyclodextrin is hydroxypropyl-beta-cyclodextrin.

Claims 26-27. (Cancelled).

Claim 28. (Original) The formulation of claim 21, wherein the concentration of Beta-lapachone in solution is at least 1 mg/ml.

Claim 29. (Cancelled).

Claim 30. (Original) A kit for the treatment of a mammalian cancer comprising at least one vial containing Beta-lapachone, or a derivative or analog thereof, according to any one of claims 1, 11 or 21.

Claim 31. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin, and further comprising a second anticancer agent and a pharmaceutically acceptable carrier.

Claim 32. (Original) The pharmaceutical composition of claim 31, wherein the composition comprises a complex or solution of the therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and the pharmaceutically acceptable solubilizing carrier molecule, and further comprises the second anticancer agent and a pharmaceutically acceptable carrier.

Claim 33. (Original) The pharmaceutical composition of claims 31 or 32, wherein the second anticancer agent is a taxane derivative.

Claim 34. (Original) The pharmaceutical composition of claim 33, wherein the taxane derivative is paclitaxel.

Claim 35. (Cancelled).

Claim 36. (Original) The pharmaceutical composition of claim 31, wherein the therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and the pharmaceutically acceptable solubilizing carrier molecule is admixed with the second anticancer agent and the pharmaceutically acceptable carrier and contained in a single vial.

Claim 37. (Original) The pharmaceutical composition of claim 31, wherein the therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and the pharmaceutically acceptable solubilizing carrier molecule is contained in a first vial, and the second anticancer agent and the pharmaceutically acceptable carrier are contained in a second vial.

Claims 38-39. (Cancelled).

Claim 40. (Previously Presented) The pharmaceutical composition of claim 31, wherein the beta-cyclodextrin is hydroxypropyl-beta-cyclodextrin.

Claims 41-42. (Cancelled).

Claim 43. (Previously Presented) The pharmaceutical composition of claim 31, wherein the concentration of Beta-lapachone in solution is at least 1 mg/ml.

Claim 44. (Cancelled).

Claim 45. (Previously Presented) A kit for the treatment of a mammalian tumor comprising one or more vials containing a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin and further comprising, within the same vial or a separate vial, a second anticancer agent.

Claim 46. (Original) The kit of claim 45, wherein the one or more vials contain a complex of the therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and the

pharmaceutically acceptable solubilizing carrier molecule and further comprising, within in the same vial or a separate vial, the second anticancer agent.

Claim 47. (Original) The kit of claims 45 or 46, wherein the second anticancer agent is a taxane derivative.

Claim 48. (Original) The kit of claim 47, wherein the taxane derivative is paclitaxel.

Claims 49-50. (Cancelled).

Claim 51. (Previously Presented) The kit of claim 45, wherein the beta-cyclodextrin is hydroxypropyl-beta-cyclodextrin.

Claims 52-53. (Cancelled).

Claim 54. (Original) The kit of claims 45 or 46, wherein the concentration of Beta-lapachone in solution is at least 1 mg/ml.

Claims 55-179 (Cancelled).

Claim 180. (Previously Presented) A sterile injectable pharmaceutical composition for intravenous administration comprising a complex of a therapeutically effective amount of Betalapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin.

Claim 181. (Cancelled)

Claim 182. (Previously Presented) The sterile injectable pharmaceutical composition of claim 180, wherein the pharmaceutically acceptable solubilizing carrier molecule is hydroxypropyl-beta-cyclodextrin.

Claim 183. (Original) The sterile injectable pharmaceutical composition of claim 180, further comprising a second anticancer agent and a pharmaceutically acceptable carrier.

Claim 184. (Original) The sterile injectable pharmaceutical composition of claim 183, wherein the second anticancer agent is a taxane derivative.

Claim 185. (Original) The sterile injectable pharmaceutical composition of claim 184, wherein the taxane derivative is paclitaxel.

Claim 186. (Original) The sterile injectable pharmaceutical composition of claim 180, wherein the concentration of Beta-lapachone in solution is at least 1 mg/ml.

Claims 187-203. (Cancelled).

Claim 204. (Previously Presented) The pharmaceutical composition of claim 1, wherein the composition comprises a therapeutically effective amount of Beta-lapachone and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin.

Claim 205. (Previously Presented) The pharmaceutical composition of claim 11, wherein the composition comprises a therapeutically effective amount of Beta-lapachone and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin, which when diluted with an aqueous solution for parenteral administration, remains soluble in the aqueous solution.

Claim 206. (Previously Presented) The formulation of claim 21, wherein the formulation comprises Beta-lapachone and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin, wherein the formulation can be freeze-dried and when subsequently reconstituted in aqueous solution is soluble.

Claim 207. (Previously Presented) The pharmaceutical composition of claim 31, wherein the composition comprises a therapeutically effective amount of Beta-lapachone and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin, and further comprising a second anticancer agent and a pharmaceutically acceptable carrier.

Claim 208. (Previously Presented) The kit of claim 45, wherein the kit comprises one or more vials containing a therapeutically effective amount of Beta-lapachone and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin and further comprising, within the same vial or a separate vial, a second anticancer agent.

Claim 209. (Previously Presented) The sterile injectable pharmaceutical composition of claim 180, wherein the composition comprises a complex of a therapeutically effective amount of Betalapachone and a pharmaceutically acceptable solubilizing carrier molecule, wherein said solubilizing carrier molecule is a beta-cyclodextrin.